For relapsing forms of MS, there are now over a dozen treatment options, which we know can be effective at stopping relapses and slowing the accumulation of disability. What we don't know is which treatment is best for different people. The DELIVER-MS study aims to show whether starting treatment with a highly effective disease-modifying therapy (DMT) improves the prognosis for people with MS. Currently, it is not known if this is any better or worse than an escalating approach, where people are only taking stronger treatments if they are necessary to control their symptoms.
The DELIVER-MS study will recruit people with relapsing-remitting MS who have not previously received a DMT. The study is designed to reflect clinical practice in MS clinics. The study will enroll people who experienced their first symptoms within the last 5 years to ensure that they get the most benefit from DMTs, mirroring regular clinical practice. The study is being led by Nottingham University Hospitals NHS Trust and aims to enroll a total of 400 people with MS from across the UK in a randomised study, and a further 400 in an observational study.
